Why IMU is a multi multi bagger, page-24336

Little power trip using selective readings, biased interpretations of interim data, accusations of outright misinformation by management, conclusions aimed at casting maximum doubts and fears in shareholders of a high risk high reward industry, without any reference to the methodologies, trial designs and unherently complicated nature of the therapies involved, all the while not having skin on the game or accountabilities.
Does not deserve any serious engagement other than derisions.
FWIW, IMU IS a high risk investment with potential high rewards same as any other biotech including RAC.
Only invest what you can afford to lose or to wait many many years for it to bear fruit.
All imho.